{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:26:29Z","timestamp":1793183189828,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673510"],"award-info":[{"award-number":["81673510"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073936"],"award-info":[{"award-number":["82073936"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U1608282"],"award-info":[{"award-number":["U1608282"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.phrs.2021.105610","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T22:11:43Z","timestamp":1618956703000},"page":"105610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy"],"prefix":"10.1016","volume":"169","author":[{"given":"Ming-Lu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2102-3810","authenticated-orcid":false,"given":"Yu-Ying","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan-You","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Feng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-8028","authenticated-orcid":false,"given":"Limei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.phrs.2021.105610_bib1","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamaneurol.2015.1017","article-title":"Mortality and morbidity during delivery hospitalization among pregnant women with epilepsy in the United States","volume":"72","author":"MacDonald","year":"2015","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105610_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ncl.2018.09.008","article-title":"Epilepsy in pregnancy","volume":"37","author":"Harden","year":"2019","journal-title":"Neurol. Clin."},{"issue":"5","key":"10.1016\/j.phrs.2021.105610_bib3","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1528-1167.2009.02129.x","volume":"50","author":"Harden","year":"2009","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.phrs.2021.105610_bib4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/epi4.12420","article-title":"Global survey of guidelines for the management of epilepsy in pregnancy: a report from the international league against epilepsy task force on women and pregnancy","volume":"5","author":"Tomson","year":"2020","journal-title":"Epilepsia Open"},{"issue":"9","key":"10.1016\/j.phrs.2021.105610_bib5","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1136\/jnnp-2013-306318","article-title":"Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland epilepsy and pregnancy registers","volume":"85","author":"Campbell","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.phrs.2021.105610_bib6","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.phrs.2021.105610_bib7","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s00415-020-09764-w","article-title":"Neurocognition after prenatal levetiracetam, lamotrigine, carbamazepine or valproate exposure","volume":"267","author":"Huber-Mollema","year":"2020","journal-title":"J. Neurol."},{"issue":"Pt 2","key":"10.1016\/j.phrs.2021.105610_bib8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/brain\/awq352","article-title":"Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age","volume":"134","author":"Meador","year":"2011","journal-title":"Brain J. Neurol."},{"issue":"4","key":"10.1016\/j.phrs.2021.105610_bib9","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ana.25321","article-title":"Lamotrigine clearance increases by 5 weeks gestational age: Relationship to estradiol concentrations and gestational age","volume":"84","author":"Karanam","year":"2018","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105610_bib10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eplepsyres.2009.02.011","article-title":"Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period","volume":"85","author":"Fotopoulou","year":"2009","journal-title":"Epilepsy Res."},{"issue":"13","key":"10.1016\/j.phrs.2021.105610_bib11","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1212\/WNL.0000000000006240","article-title":"Antiepileptic drug clearances during pregnancy and clinical implications for women with epilepsy","volume":"91","author":"Voinescu","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.phrs.2021.105610_bib12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/00498250902745082","article-title":"Variation in glucuronidation of lamotrigine in human liver microsomes","volume":"39","author":"Argikar","year":"2009","journal-title":"Xenobiotica Fate Foreign Compd. Biol. Syst."},{"issue":"8","key":"10.1016\/j.phrs.2021.105610_bib13","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.neuropharm.2008.08.032","article-title":"Several major antiepileptic drugs are substrates for human P-glycoprotein","volume":"55","author":"Luna-Tort\u00f3s","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2021.105610_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neuropharm.2015.01.015","article-title":"The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2)","volume":"93","author":"R\u00f6mermann","year":"2015","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.phrs.2021.105610_bib15","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.bcp.2011.12.032","article-title":"Lamotrigine is a substrate for OCT1 in brain endothelial cells","volume":"83","author":"Dickens","year":"2012","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.phrs.2021.105610_bib16","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00228-014-1690-1","article-title":"Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China","volume":"70","author":"Chang","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105610_bib17","first-page":"4107","article-title":"Association of UGT2B7 and UGT1A4 polymorphisms with serum concentration of antiepileptic drugs in children","volume":"22","author":"Du","year":"2016","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"issue":"2","key":"10.1016\/j.phrs.2021.105610_bib18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bcp.12984","article-title":"Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: influence of polymorphism of UDP-glucuronosyltransferases and drug transporters","volume":"82","author":"Milosheska","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105610_bib19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.eplepsyres.2018.01.011","article-title":"UGT polymorphisms and lamotrigine clearance during pregnancy","volume":"140","author":"Petrenaite","year":"2018","journal-title":"Epilepsy Res."},{"issue":"5","key":"10.1016\/j.phrs.2021.105610_bib20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1080\/09513590.2018.1564742","article-title":"Steroid hormones and pregnancy","volume":"35","author":"Noyola-Mart\u00ednez","year":"2019","journal-title":"Gynecol. Endocrinol. Off. J. Int. Soc. Gynecol. Endocrinol."},{"issue":"10","key":"10.1016\/j.phrs.2021.105610_bib21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00003088-200544100-00001","article-title":"Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach","volume":"44","author":"Anderson","year":"2005","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.phrs.2021.105610_bib22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/epi.12109","article-title":"Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications","volume":"54","author":"Tomson","year":"2013","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.phrs.2021.105610_bib23","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1124\/dmd.109.026609","article-title":"Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy","volume":"37","author":"Chen","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"22 Pt 2","key":"10.1016\/j.phrs.2021.105610_bib24","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1212\/01.wnl.0000289511.20864.2a","article-title":"Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency","volume":"70","author":"Pennell","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.phrs.2021.105610_bib25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.eplepsyres.2011.02.002","article-title":"Lamotrigine and its N2-glucuronide during pregnancy: the significance of renal clearance and estradiol","volume":"94","author":"Reimers","year":"2011","journal-title":"Epilepsy Res."},{"issue":"6","key":"10.1016\/j.phrs.2021.105610_bib26","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1528-1167.2007.01471.x","article-title":"Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy","volume":"49","author":"Ohman","year":"2008","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.phrs.2021.105610_bib27","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10995-018-02705-0","article-title":"Predictors of steroid hormone concentrations in early pregnancy: results from a multi-center cohort","volume":"23","author":"Barrett","year":"2019","journal-title":"Matern. Child Health J."},{"issue":"6","key":"10.1016\/j.phrs.2021.105610_bib28","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/FTD.0000000000000563","article-title":"A population pharmacokinetic-pharmacogenetic model of lamotrigine in chinese children with epilepsy","volume":"40","author":"Chen","year":"2018","journal-title":"Ther. Drug Monit."},{"issue":"2","key":"10.1016\/j.phrs.2021.105610_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/acn3.29","article-title":"Model-based lamotrigine clearance changes during pregnancy: clinical implication","volume":"1","author":"Polepally","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.phrs.2021.105610_bib30","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.phrs.2021.105610_bib31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2125.1994.tb05705.x","article-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH)","volume":"37","author":"Baber","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.phrs.2021.105610_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1315","article-title":"Pharmacokinetic changes and therapeutic drug monitoring of lamotrigine during pregnancy","volume":"9","author":"Ding","year":"2019","journal-title":"Brain Behav."},{"issue":"5","key":"10.1016\/j.phrs.2021.105610_bib33","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00228-018-2414-8","article-title":"Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling","volume":"74","author":"Xu","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.phrs.2021.105610_bib34","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40262-017-0614-5","article-title":"Effect of age-related factors on the pharmacokinetics of lamotrigine and potential implications for maintenance dose optimisation in future clinical trials","volume":"57","author":"van Dijkman","year":"2018","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.phrs.2021.105610_bib35","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1111\/epi.14519","article-title":"Lamotrigine pharmacokinetics following oral and stable-labeled intravenous administration in young and elderly adult epilepsy patients: Effect of age","volume":"59","author":"Polepally","year":"2018","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.phrs.2021.105610_bib36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bcp.13431","article-title":"External evaluation of population pharmacokinetic models for ciclosporin in adult renal transplant recipients","volume":"84","author":"Mao","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2021.105610_bib37","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/bcp.13850","article-title":"Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co-administered with tacrolimus","volume":"85","author":"Zhang","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105610_bib38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00265-010-1029-6","article-title":"AIC model selection and multimodel inference in behavioral ecology: some background, observations, and comparisons","volume":"65","author":"Burnham","year":"2011","journal-title":"Behav. Ecol. Sociobiol."},{"key":"10.1016\/j.phrs.2021.105610_bib39","doi-asserted-by":"crossref","unstructured":"P.K. Burnham, Multimodel Inference Understanding AIC and BIC in Model Selection, 33(2), 2004, pp. 261\u2013304.","DOI":"10.1177\/0049124104268644"},{"issue":"7","key":"10.1016\/j.phrs.2021.105610_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/psp.2013.26","article-title":"Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance","volume":"2","author":"Byon","year":"2013","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"issue":"11","key":"10.1016\/j.phrs.2021.105610_bib41","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/aps.2012.135","article-title":"The effect of poor compliance on the pharmacokinetics of carbamazepine and its epoxide metabolite using Monte Carlo simulation","volume":"33","author":"Ding","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.phrs.2021.105610_bib42","unstructured":"T.N.C.f.B. Information, Single Nucleotide Polymorphism Database, September 1998. Available at: \u3008https:\/\/www.ncbi.nlm.nih.gov\/snp\/\u3009. (Accessed August 2020)."},{"issue":"4","key":"10.1016\/j.phrs.2021.105610_bib43","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/0091270007313391","article-title":"Population pharmacokinetics of lamotrigine in elderly patients","volume":"48","author":"Punyawudho","year":"2013","journal-title":"J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2021.105610_bib44","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/ane.12197","article-title":"Effect of oral contraceptives on lamotrigine levels depends on comedication","volume":"129","author":"Wegner","year":"2014","journal-title":"Acta Neurol. Scand."},{"issue":"12","key":"10.1016\/j.phrs.2021.105610_bib45","doi-asserted-by":"crossref","first-page":"752","DOI":"10.5414\/CPP47752","article-title":"Population pharmacokinetics of lamotrigine in patients with epilepsy","volume":"47","author":"Milovanovic","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2021.105610_bib46","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40262-014-0212-8","article-title":"A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation","volume":"54","author":"Ding","year":"2015","journal-title":"Clin. Pharmacokinet."},{"issue":"5\u20136","key":"10.1016\/j.phrs.2021.105610_bib47","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10928-005-0083-6","article-title":"Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses","volume":"32","author":"Ahn","year":"2005","journal-title":"J. Pharmacokinet Pharmacodyn."},{"issue":"2","key":"10.1016\/j.phrs.2021.105610_bib48","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.seizure.2007.11.017","article-title":"Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites","volume":"17","author":"Ohman","year":"2008","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.phrs.2021.105610_bib49","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2125.2005.02539.x","article-title":"The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects","volume":"61","author":"Sidhu","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105610_bib50","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1111\/epi.13597","article-title":"Hormone replacement therapy with estrogens may reduce lamotrigine serum concentrations: a matched case-control study","volume":"58","author":"Reimers","year":"2017","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.phrs.2021.105610_bib51","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/GME.0000000000000855","article-title":"Estriol: emerging clinical benefits","volume":"24","author":"Ali","year":"2017","journal-title":"Menopause"},{"key":"10.1016\/j.phrs.2021.105610_bib52","series-title":"Individual Administration Study of Lamotrigine given to Chinese Southern Epilepsy Patients Based on PharmacogenomIcs","author":"Yan-ling","year":"2017"},{"issue":"7","key":"10.1016\/j.phrs.2021.105610_bib53","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40262-015-0267-1","article-title":"Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literature","volume":"54","author":"Wolking","year":"2015","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.phrs.2021.105610_bib54","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.eplepsyres.2014.03.019","article-title":"The ABCB1-C3435T polymorphism likely acts as a risk factor for resistance to antiepileptic drugs","volume":"108","author":"Li","year":"2014","journal-title":"Epilepsy Res."},{"issue":"5","key":"10.1016\/j.phrs.2021.105610_bib55","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/FTD.0b013e31826517c6","article-title":"Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy","volume":"34","author":"Lovri\u0107","year":"2012","journal-title":"Ther. Drug Monit."},{"issue":"6","key":"10.1016\/j.phrs.2021.105610_bib56","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00403-018-1842-8","article-title":"Haplotypes of ABCB1 1236C\u2009>T (rs1128503), 2677G\u2009>T\/A (rs2032582), and 3435C\u2009>T (rs1045642) in patients with bullous pemphigoid","volume":"310","author":"Rychlik-Sych","year":"2018","journal-title":"Arch. Dermatol. Res."},{"issue":"2","key":"10.1016\/j.phrs.2021.105610_bib57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF03191157","article-title":"Lamotrigine and valproate pharmacokinetics interactions in epileptic patients","volume":"34","author":"Lalic","year":"2009","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.phrs.2021.105610_bib58","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(11)70107-7","article-title":"Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry","volume":"10","author":"Tomson","year":"2011","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.phrs.2021.105610_bib59","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/14656566.2018.1550073","article-title":"Therapeutic strategies for treating epilepsy during pregnancy","volume":"20","author":"Whelehan","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.phrs.2021.105610_bib60","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/CLEP.S118336","article-title":"Antiepileptic drugs prescribed in pregnancy and prevalence of major congenital malformations: comparative prevalence studies","volume":"9","author":"Petersen","year":"2017","journal-title":"CLEP"},{"key":"10.1016\/j.phrs.2021.105610_bib61","doi-asserted-by":"crossref","first-page":"k1609","DOI":"10.1136\/bmj.k1609","article-title":"Dangers of valproate in pregnancy","volume":"361","author":"Wieck","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2021.105610_bib62","doi-asserted-by":"crossref","first-page":"k1823","DOI":"10.1136\/bmj.k1823","article-title":"MHRA bans valproate prescribing for women not in pregnancy prevention programme","volume":"361","author":"Iacobucci","year":"2018","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.phrs.2021.105610_bib63","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/epi.13021","article-title":"Valproate in the treatment of epilepsy in girls and women of childbearing potential","volume":"56","author":"Tomson","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.phrs.2021.105610_bib64","article-title":"Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child","volume":"11","author":"Weston","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2021.105610_bib65","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12884-018-1842-x","article-title":"Sodium valproate in pregnancy: what are the risks and should we use a shared decision-making approach?","volume":"18","author":"Macfarlane","year":"2018","journal-title":"BMC Pregnancy Childbirth"},{"issue":"3","key":"10.1016\/j.phrs.2021.105610_bib66","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","article-title":"Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study","volume":"12","author":"Meador","year":"2013","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.phrs.2021.105610_bib67","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.phrs.2021.105610_bib68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821001948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821001948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:26:14Z","timestamp":1760912774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821001948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":68,"alternative-id":["S1043661821001948"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105610","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105610","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105610"}}